# Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies

## TL;DR

This paper explores why anti-amyloid drugs cause brain volume changes and calls for more open sharing of clinical trial data.

## Contribution

The paper provides a novel argument for resolving brain volume loss paradoxes through data transparency in Alzheimer's drug trials.

## Key findings

- Anti-amyloid therapies are linked to paradoxical brain volume changes.
- The authors propose that data transparency could clarify these effects.
- Uncertainty remains about the long-term benefits of these drugs.

## Abstract

Anti-amyloid drugs modestly slow Alzheimer’s disease progression, albeit with uncertainty of sustained benefit, particularly as they cause paradoxical acceleration of brain volume changes. Here, we examine explanations for these volume changes and argue for transparent release of clinical trial data.